H index: 12 (Scopus), 12 (Google Scholar)
i10-index (Google Scholar): 14

FORMAZIONE
2024, Dottorato di ricerca in Neuroscienze, Università di Firenze
2020, Specializzazione in Neurologia, Università di Firenze
2019, Corso di perfezionamento “La valutazione neuropsicologica delle malattia neurodegenerative”, Università di Pisa
2015, Laurea in Medicina e Chirurgia, Università “Vita-Salute” San Raffaele, Milano

FELLOWSHIPS
2023, Visiting Research Fellow, Dementia Research Centre, University College of London, Londra, UK

ATTIVITÀ CLINICA
2024 – oggi, Unità di Neurologia, IRCCS “San Donato”, San Donato Milanese
2020 – 2023, Neurologo riabilitatore, Unità di Neuroriabilitazione Intensiva, IRCCS “Don Carlo Gnocchi”, Firenze
2016 – 2020, Medico in formazione specialistica, Azienda Ospedaliero-Universitaria, Careggi, Firenze

ATTIVITÀ DI RICERCA
2024 – oggi, Ricercatore a tempo determinato di tipo B in Neurologia, Università Vita-Salute San Raffaele, Milano
2023 – 2024, Senior Researcher, Azienda Ospedaliero-Universitaria, Careggi, Firenze
2020 – 2024, Dottorando di ricerca in Neuroscienze, Università di Firenze
2022, Assistente ricercatore, IRCCS “Don Carlo Gnocchi”, Firenze
2015 – 2016, Collaboratore medico ricercatore, Institute of Experimental Neurology (INSPE), IRCCS, Ospedale San Raffaele, Milano


RUOLI IN SOCIETÀ SCIENTIFICHE
2021 – oggi, Membro eletto del Consiglio Direttivo, SINdem sezione Toscana

PREMI E RICONOSCIMENTI
2024, Junior Faculty Award - 18th International Conference on Alzheimer's & Parkinson's Diseases and related neurological disorders
2023, American Academy of Neurology’s (AAN) International Scholarship Award
2021, Vincitore 2° classificato del premio "La ricerca in 3 minuti" Award – Notte Europea dei ricercatori, Università di Firenze
2020, Miglior poster, Congresso della Società Italian per lo Studio delle Demenze (SINDEM)
2020, Miglior poster, Winter seminar on Dementia and Neurodegenerative Disorders, Bressanone
2018, Miglior presentazione orale, Winter seminar on Dementia and Neurodegenerative Disorders, Bressanone

PUBBLICAZIONI
1. Mazzeo S, Santangelo R, Bernasconi MP, et al. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. J Alzheimers Dis. 2016;54(4):1495-1508. doi:10.3233/JAD-160360
2. Mazzeo S, Padiglioni S, Bagnoli S, et al. Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer’s disease: an 11-year follow-up study. Eur J Neurol. 2020;27(5):894-899. doi:10.1111/ene.14167
3. Mazzeo S, Emiliani F, Bagnoli S, et al. Huntingtin gene intermediate alleles influence the progression from subjective cognitive decline to mild cognitive impairment: A 14-year follow-up study. Eur J Neurol. 2022;29(6):1600-1609. doi:10.1111/ene.15291
4. Mazzeo S, Bessi V, Bagnoli S, et al. Dual Effect of PER2 C111G Polymorphism on Cognitive Functions across Progression from Subjective Cognitive Decline to Mild Cognitive Impairment. Diagnostics. 2021;11(4):718. doi:10.3390/diagnostics11040718
5. Mazzeo S, Bessi V, Padiglioni S, et al. KIBRA T allele influences memory performance and progression of cognitive decline: a 7-year follow-up study in subjective cognitive decline and mild cognitive impairment. Neurol Sci. 2019;40(8):1559-1566. doi:10.1007/s10072-019-03866-8
6. Mazzeo S, Polito C, Lassi M, et al. Loss of speech and functional impairment in Alzheimer’s disease-related primary progressive aphasia: predictive factors of decline. Neurobiol Aging. 2022;117:59-70. doi:10.1016/j.neurobiolaging.2022.05.002
7. Mazzeo S, Polito C, Padiglioni S, et al. Linguistic profiles, brain metabolic patterns and rates of amyloid-β biomarker positivity in patients with mixed primary progressive aphasia. Neurobiol Aging. 2020;96:155-164. doi:10.1016/j.neurobiolaging.2020.09.004
8. Mazzeo S, Padiglioni S, Bagnoli S, et al. The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study. J Neurol. 2019;266(2):487-497. doi:10.1007/s00415-018-9164-5
9. Mazzeo S, Emiliani F, Bagnoli S, et al. Alzheimer’s Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus. Journal of Personalized Medicine. 2022;12(6):935. doi:10.3390/jpm12060935
10. Mazzeo, S., Lassi, M., Padiglioni, S. et al. PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer’s Disease With machine learning: the PREVIEW study protocol. BMC Neurol 23, 300 (2023). https://doi.org/10.1186/s12883-023-03347-8
11. Mazzeo S, Ingannato A, Giacomucci G, et al. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment. Neurol Sci. Published online September 19, 2023. doi:10.1007/s10072-023-07065-4
12. Mazzeo S, Ingannato A, Giacomucci G, et al. Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study. Eur J Neurol. Published online October 5, 2023. doi:10.1111/ene.16089
13. Mazzeo S, Pancani S, Sodero A, et al. Depressive Symptoms Moderate the Association Between Functional Level at Admission to Intensive Post-Stroke Rehabilitation and Effectiveness of the Intervention. J Geriatr Psychiatry Neurol. Published online October 12, 2023:8919887231204543. doi:10.1177/08919887231204543
14. Bessi V and Mazzeo S, Bagnoli S, et al. The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer’s disease: a 9-year follow-up study. Eur Arch Psychiatry Clin Neurosci. 2020;270(4):471-482. doi:10.1007/s00406-019-01069-y
15. Giacomucci G and Mazzeo S, Bagnoli S, et al. Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment. J Neurol. 2022;269(8):4270-4280. doi:10.1007/s00415-022-11055-5
16. Giacomucci G and Mazzeo S, Padiglioni S, et al. Gender differences in cognitive reserve: implication for subjective cognitive decline in women. Neurol Sci. 2022;43(4):2499-2508. doi:10.1007/s10072-021-05644-x
17. Bessi V and Mazzeo S, Bagnoli S, et al. The Effect of CAG Repeats within the Non-Pathological Range in the HTT Gene on Cognitive Functions in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Diagnostics. 2021;11(6):1051. doi:10.3390/diagnostics11061051
18. Bessi V, Mazzeo S, Padiglioni S, et al. From Subjective Cognitive Decline to Alzheimer’s Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study. Journal of Alzheimer’s Disease. 2018;63(4):1523-1535. doi:10.3233/JAD-171180
19. Bessi V, Giacomucci G, Mazzeo S, et al. PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: a 10-year follow-up study. European Journal of Neurology. 2021;28(1):56-65. doi:10.1111/ene.14518
20. Giacomucci G, Mazzeo S, Crucitti C, et al. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer’s disease pathology in subjective cognitive decline and mild cognitive impairment. Journal of the Neurological Sciences. 2023;0(0). doi:10.1016/j.jns.2023.120805
21. Bessi V, Balestrini J, Bagnoli S, Mazzeo S, et al. Influence of ApoE Genotype and Clock T3111C Interaction with Cardiovascular Risk Factors on the Progression to Alzheimer's Disease in Subjective Cognitive Decline and Mild Cognitive Impairment Patients. J Pers Med. 2020 May 29;10(2):45. doi: 10.3390/jpm10020045. PMID: 32485802; PMCID: PMC7354597.
22. Moschini V, Mazzeo S, Bagnoli S, et al. CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study. Frontiers in Psychiatry. 2022;13. Accessed April 6, 2023. https://www.frontiersin.org/articles/10.3389/fpsyt.2022.826135
23. Nerattini M, Rubino F, Arnone A, Polito C, Mazzeo S, et al. Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. Neurol Sci. 2022;43(4):2469-2480. doi:10.1007/s10072-021-05704-2
24. Ingannato A, Bagnoli S, Mazzeo S, et al. Neurofilament Light Chain and Intermediate HTT Alleles as Combined Biomarkers in Italian ALS Patients. Frontiers in Neuroscience. 2021;15. Accessed April 7, 2023. https://www.frontiersin.org/articles/10.3389/fnins.2021.695049
25. Lassi M, Fabbiani C, Mazzeo S, et al. Degradation of EEG microstates patterns in subjective cognitive decline and mild cognitive impairment: Early biomarkers along the Alzheimer’s Disease continuum? NeuroImage: Clinical. 2023;38:103407. doi:10.1016/j.nicl.2023.103407
26. Ingannato A, Bagnoli S, Bessi V, Ferrari C, Mazzeo S, et al. Intermediate alleles of HTT: A new pathway in longevity. Journal of the Neurological Sciences. 2022;438:120274. doi:10.1016/j.jns.2022.120274
27. Giacomucci G, Polito C, Berti V, Padiglioni S, Galdo G, Mazzeo S, et al. Differences and Similarities in Empathy Deficit and Its Neural Basis between Logopenic and Amnesic Alzheimer’s Disease. Journal of Personalized Medicine. 2023;13(2):208. doi:10.3390/jpm13020208
28. Giacomucci G, Mazzeo S, Bagnoli S, et al. Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia. Journal of Personalized Medicine. 2021;11(1):47. doi:10.3390/jpm11010047
29. Giacomucci G, Galdo G, Polito C, Berti V, Padiglioni S, Mazzeo S, et al. Unravelling neural correlates of empathy deficits in Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer’s Disease. Behavioural Brain Research. 2022;428:113893. doi:10.1016/j.bbr.2022.113893
30. Clarelli F, Mascia E, Santangelo R, Mazzeo S, et al. CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer’s Disease Patients. Journal of Alzheimer’s Disease. 2016;52(4):1203-1208. doi:10.3233/JAD-160074
31. Carraro M, Ferrari C, Latorraca S, Mazzeo S, et al. Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma. Clinical Neurology and Neurosurgery. 2020;190:105638. doi:10.1016/j.clineuro.2019.105638
32. Sodero A, Squitieri M, Mazzeo S, et al. Acute Symptomatic Sinus Bradycardia in High-Dose Methylprednisolone Therapy in a Woman With Inflammatory Myelitis: A Case Report and Review of the Literature. Clin Med Insights Case Rep. 2019;12:1179547619831026. doi:10.1177/1179547619831026
33. Pasca M, Picchioni A, Mazzeo S, et al. A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet. Intractable Rare Dis Res. 2019;8(4):275-278. doi:10.5582/irdr.2019.01107
34. Canu E, Bessi V, Calderaro D, Simoni D, Castelnovo V, Leocadi M, Padiglioni S, Masseo S, et al. Early functional MRI changes in a prodromal semantic variant of primary progressive aphasia: a longitudinal case report. J Neurol. 2020;267(10):3100-3104. doi:10.1007/s00415-020-10053-9
35. Bellelli G, Morandi A, Di Santo SG, et al. “Delirium Day”: A nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. BMC Medicine. 2016;14(1). doi:10.1186/s12916-016-0649-8
36. Morandi A, Zambon A, Di Santo SG, et al. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia. J Am Med Dir Assoc. 2020;21(4):486-492.e7. doi:10.1016/j.jamda.2020.02.013
37. Lopez A, Lee SE, Wojta K, et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain. 2017;140(4):1128-1146. doi:10.1093/brain/awx005
38. Polito C, Conca F, Santi GC, Esposito V, Caminiti SP, Boccalini C, Berti V, Morinelli C, Mazzeo S, Marcone A, Iannaccone S, Bessi V, Sorbi S, Perani D, Cappa SF, Catricalà E. Comparing two picture naming tasks in primary progressive aphasia: Insights from behavioural and neural results. Cortex. 2023 Sep;166:1-18. doi: 10.1016/j.cortex.2023.04.014. Epub 2023 May 21. PMID: 37295234.
39. Belder CRS, Marshall CR, Jiang J, et al. Primary progressive aphasia: six questions in search of an answer. J Neurol. 2024;271(2):1028-1046. doi:10.1007/s00415-023-12030-4
40. Amato LG, Vergani AA, Lassi M, et al. Personalized modeling of Alzheimer’s disease progression estimates neurodegeneration severity from EEG recordings. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2024;16(1):e12526. doi:10.1002/dad2.12526
41. Giacomucci G, Moschini V, Piazzesi D, et al. Disentangling empathy impairment along Alzheimer’s disease continuum: From subjective cognitive decline to Alzheimer’s dementia. Cortex. 2024;172:125-140. doi:10.1016/j.cortex.2023.12.009

Conference Presentations – Oral communications
• 9th Congress of the European Academy of Neurology, Budapest, Hungary, 2022
S. Mazzeo, M. Lassi, S. Padiglioni, et al. Machine learning model to predict progression from subjective to objective cognitive decline: a 14-year follow-up study
• American Academy of Neurology Annual Meeting, Boston, USA, 2023
S. Mazzeo, V. Moschini, S. Padiglioni et al. Subjective cognitive decline: a proposal for a management protocol based on review of literature and 15 years’ experience from a memory clinic
• 52nd Annual Congress of the Italian Society of Neurology, Milan, Italy, 2022
• S. Mazzeo, S. Bagnoli, A. Manganelli et al. Plasma neurofilament light chain predicts Alzheimer’s disease and progression of cognitive decline in patients with subjective cognitive decline and mild cognitive impairment: a longitudinal study
• 8th Congress of the European Academy of Neurology, Vienna, Austria, 2022
S. Mazzeo, Padiglioni S, Bagnoli S, et al. Subjective cognitive decline: 15 years of follow-up experience from a memory clinic
• American Academy of Neurology Annual Meeting, Seattle, USA, 2022
Mazzeo, S. Bagnoli, S. Padiglioni et al. Huntingtin gene intermediate alleles influence the progression from Subjective Cognitive Decline to Mild Cognitive Impairment: a 15-year follow-up study (P18-3.003).
• XXIX Congress of the Italian Society of Psychophysiology "Beyond the lockdown of the brain", Palermo, Italy, 2021
S. Mazzeo, C. Polito, S. Bagnoli, et al. Loss of speech and functional impairment in Alzheimer’s disease-related primary progressive aphasia: predictive factors of decline
• XXV World Congress of Neurology (WCN 2021), Virtual congress, 2021
S. Mazzeo, C. Polito, M. Mattei, et al. Predictive factors of progression to total loss of language and functional autonomy in primary progressive aphasia related to Alzheimer’s disease (DOI: 10.1016/j.jns.2021.117851)
• 51st Annual Conference of the Italian Society of Neurology, Virtual, 2021. S. Mazzeo, M. Mattei, C. Polito, S. Bagnoli, et al. Cerebrospinal fluid total-tau concentration and brain hypometabolism predict progression to total loss of language in Alzheimer-related Primary Progressive Aphasia.
• 7th Congress of the European Academy of Neurology, Virtual congress, 2021
S. Mazzeo, V Bessi, S Bagnoli, et al. HTT gene CAG repeat length influence cognitive functions in subjective cognitive decline and mild cognitive impairment.
• 6th Congress of the European Academy of Neurology, Virtual congress, 2020
S. Mazzeo, C. Polito, S. Padiglioni, et al. Characterization of mixed primary progressive aphasia: language, functional neuroimaging and pathological features.
• 8th Winter seminar on Dementia and Neurodegenerative Disorders, Brixen, Italy, January 2020
Salvatore Mazzeo, S. Padiglioni, S. Bagnoli, et al. Assessing the effectiveness of SCD-plus criteria in predicting the progression to Alzheimer's Disease: A 10-year follow-up study.
• 5th Congress of the European Academy of Neurology, Oslo, Norawy, 2019
Mazzeo S, Padiglioni S, Polito C, et al. Concordance among neuropsychological profile, functional and pathological biomarkers in Primary Progressive Aphasia: a single centre experience.
• 7th Scientific meeting of the Federation of the European Societies of Neuropsychology, Milan, Italy, 2019
Mazzeo S, Padiglioni S, Polito C, et al. Language features, functional and pathological biomarkers in Primary Progressive Aphasia. A single-centre experience.
• 50th Annual Congress of the Italian Society of Neurology, Bologna, Italy, 2019
Mazzeo S, Padiglioni S, Bagnoli S. Validation of Subjective Cognitive Decline-plus (SCD-plus) criteria: the effect of demographic and genetic features on the risk of progression from SCD to AD. A 10-year follow-up study
• 49th Annual Congress of the Italian Society of Neurology, Rome, Italy, 2018
Mazzeo S, Padiglioni S, Bagnoli S, et al. The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study.
• 13° Annual Congress of the Italian Association for the study of Dementia, Florence, Italy, 2018
Mazzeo S, Bessi V, Padiglioni S, et al. KIBRA gene variants are associated with cognitive performance in Subjective Cognitive Decline and Mild Cognitive Impairment
• Regional meeting on Movement Disorders (Tuscany), Italy, 2018
S.Mazzeo, V. Bessi, A. Novelli, et al. Emicorea/emiballismo associato a decadimento cognitivo e disturbo del comportamento: il ritorno di una vecchia conoscenza?
• 48th Annual Congress of the Italian Society of Neurology, Naples, Italy, 2017
Mazzeo S, Bessi V, Padiglioni S, et al. Neuropsychological and personality assessment in Subjective Memory Complaint and Mild Cognitive Impairment: data from a 20-years follow-up study.
• 4th Winter seminar on Dementia and Neurodegenerative Disorders, Brixen, Italy, 2016
Mazzeo S, Santangelo R, Cecchetti G, et al. Potential role of Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment in progression from Mild Cognitive Impairment to Alzheimer’s Dementia.

Conference Presentations – Poster
• Alzheimer's Association International Conference, Amsterdam, Netherlands, 2023
S. Mazzeo, M. Lassi, et al. A machine learning model to predict progression from subjective cognitive decline to mild cognitive impairment and dementia: a 12-year follow-up study
S. Mazzeo, S. Bagnoli, A. Ingannato et al. Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: a longitudinal study
• 9th Congress of the European Academy of Neurology, Budapest, Hungary, 2022
S. Mazzeo, C. Morinelli, C. Polito, et al. Data-driven subtypes of mixed semantic-logopenic primary progressive aphasia: language and biomarker profiles
• 15th Annual Congress of the Italian Association for the study of Dementia, Florence, Italy, 2022
S. Mazzeo, S. Bagnoli, G. Giacomucci, et al. Plasma neurofilament light chain predicts Alzheimer’s pathology and progression of cognitive decline in patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
• American Academy of Neurology Annual Meeting, 2020 (Canceled).
Mazzeo S, Polito C, Padiglioni S, Berti V, Bagnoli S, Lombardi G, Piaceri I, Carraro M, Ferrari C, Nacmias B, Sorbi S, Bessi V. Concordance among neuropsychological profile, functional neuroimaging and pathological biomarkers in Primary Progressive Aphasia. A single-centre experience.
• 7th Winter seminar on Dementia and Neurodegenerative Disorders, Brixen, Italy, January 2019
S. Mazzeo, S. Padiglioni, S. Bagnoli, C. Polito, V. Berti, G. Lombardi, I. Piaceri, C. Ferrari, B. Nacmias, S. Sorbi, V. Bessi. Understanding Aphasia: defining concordance among neuropsychological profile, functional and pathological biomarkers in Primary Progressive Aphasia. (Accepted as poster)
• 14th Annual Congress of the Italian Association for the study of Dementia, Florence, Italy, 2019
Mazzeo S, Padiglioni S, Bagnoli S. Understanding Aphasia: defining concordance among neuropsychological profile, functional and pathological biomarkers in Primary Progressive Aphasia.
• 6th Winter seminar on Dementia and Neurodegenerative Disorders, Brixen, Italy, 2018
Mazzeo S, Bessi V, Padiglioni S, et al. KIBRA gene variants are associated with cognitive performance in Subjective Cognitive Decline and Mild Cognitive Impairment.